Discovery of biaryls as ROR gamma inverse agonists by using structure-based design.
Enyedy, I.J., Powell, N.A., Caravella, J., van Vloten, K., Chao, J., Banerjee, D., Marcotte, D., Silvian, L., McKenzie, A., Hong, V.S., Fontenot, J.D.(2016) Bioorg Med Chem Lett 26: 2459-2463
- PubMed: 27080181 
- DOI: https://doi.org/10.1016/j.bmcl.2016.03.109
- Primary Citation of Related Structures:  
5EJV, 5ETH - PubMed Abstract: 
ROR¦Ã plays a critical role in controlling a pro-inflammatory gene expression program in several lymphocyte lineages including T cells, ¦Ã¦Ä T cells, and innate lymphoid cells. ROR¦Ã-mediated inflammation has been linked to susceptibility to Crohn's disease, arthritis, and psoriasis. Thus inverse agonists of ROR¦Ã have the potential of modulating inflammation. Our goal was to optimize two ROR¦Ã inverse agonists: T0901317 from literature and 1 that we obtained from internal screening. We used information from internal X-ray structures to design two libraries that led to a new biaryl series.
Organizational Affiliation: 
Biogen, 250 Binney St., Cambridge, MA 02142, USA. Electronic address: istvan.enyedy@biogen.com.